TRDA Key Statistics, Chart & Performance
The current stock price of TRDA is 10.11 USD. In the past month the price increased by 48.02%. In the past year, price decreased by -46.22%.
TRDA Latest News, Press Relases and Analysis
TRDA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 25 | 417.40B | ||
| AMGN | AMGEN INC | 15.43 | 181.72B | ||
| GILD | GILEAD SCIENCES INC | 15.46 | 157.14B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.58 | 109.42B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.79 | 80.12B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 855.65 | 57.20B | ||
| INSM | INSMED INC | N/A | 42.01B | ||
| NTRA | NATERA INC | N/A | 31.65B | ||
| BIIB | BIOGEN INC | 10.47 | 25.70B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.99 | 21.48B | ||
| INCY | INCYTE CORP | 15.9 | 19.93B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.10B |
Related stock screener links
About TRDA
Company Profile
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company is headquartered in Boston, Massachusetts and currently employs 183 full-time employees. The company went IPO on 2021-10-29. The company is engaged in establishing a class of medicines, which engages intracellular targets. Its Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. The firm is advancing a robust development portfolio of RNA-, antibody- and enzyme-based programs for the potential treatment of neuromuscular, ocular, metabolic and immunological diseases, among others. The company is engaged in preclinical lead optimization efforts in both neuromuscular and non-neuromuscular disease and discovery efforts to advance platform applications. Its lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne who are exon 44, 45, 50 and 51 skipping amenable. The company has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
Company Info
ENTRADA THERAPEUTICS INC
One Design Center Place, Suite 17-500
Boston MASSACHUSETTS US
CEO: Dipal Doshi
Employees: 183
Phone: 18573051825
ENTRADA THERAPEUTICS INC / TRDA FAQ
Can you describe the business of ENTRADA THERAPEUTICS INC?
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company is headquartered in Boston, Massachusetts and currently employs 183 full-time employees. The company went IPO on 2021-10-29. The company is engaged in establishing a class of medicines, which engages intracellular targets. Its Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. The firm is advancing a robust development portfolio of RNA-, antibody- and enzyme-based programs for the potential treatment of neuromuscular, ocular, metabolic and immunological diseases, among others. The company is engaged in preclinical lead optimization efforts in both neuromuscular and non-neuromuscular disease and discovery efforts to advance platform applications. Its lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne who are exon 44, 45, 50 and 51 skipping amenable. The company has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
What is the stock price of ENTRADA THERAPEUTICS INC today?
The current stock price of TRDA is 10.11 USD. The price increased by 10.25% in the last trading session.
What is the dividend status of ENTRADA THERAPEUTICS INC?
TRDA does not pay a dividend.
What is the ChartMill rating of ENTRADA THERAPEUTICS INC stock?
TRDA has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Is ENTRADA THERAPEUTICS INC (TRDA) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on TRDA.
When does ENTRADA THERAPEUTICS INC (TRDA) report earnings?
ENTRADA THERAPEUTICS INC (TRDA) will report earnings on 2026-02-25, after the market close.
Can you provide the short interest for TRDA stock?
The outstanding short interest for ENTRADA THERAPEUTICS INC (TRDA) is 2.74% of its float.
TRDA Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to TRDA. When comparing the yearly performance of all stocks, TRDA is one of the better performing stocks in the market, outperforming 77.69% of all stocks.
TRDA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to TRDA. While TRDA has a great health rating, there are worries on its profitability.
TRDA Financial Highlights
Over the last trailing twelve months TRDA reported a non-GAAP Earnings per Share(EPS) of -2.49. The EPS decreased by -256.6% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -25.06% | ||
| ROE | -30.36% | ||
| Debt/Equity | 0 |
TRDA Forecast & Estimates
10 analysts have analysed TRDA and the average price target is 16.83 USD. This implies a price increase of 66.47% is expected in the next year compared to the current price of 10.11.
For the next year, analysts expect an EPS growth of -288.51% and a revenue growth -78.96% for TRDA